| Created at | Source | Raw Value | Validated value |
|---|---|---|---|
| July 4, 2024, 8 a.m. | usa |
Clinical Activity (Response)(Phase 2);Maximum Tolerated Dose (MTD) (Phase 1) |
Clinical Activity (Response)(Phase 2);Maximum Tolerated Dose (MTD) (Phase 1) |
| Oct. 26, 2020, 11:31 p.m. | usa |
Incidence of toxicity, graded according to the NCI CTCAE version 5;Maximum tolerated dose (MTD) (Phase 1);Clinical activity (Response)(Phase 2) |
Incidence of toxicity, graded according to the NCI CTCAE version 5;Maximum tolerated dose (MTD) (Phase 1);Clinical activity (Response)(Phase 2) |